$RHHBY

$VYMI offers 3.3% dividend yield with 1,500+ stocks and 0.07% fees, outperforming S&P 500 with 24% annual returns for income-focused retirees.

Roche launches cobas eplex RP3, detecting 25 pathogens simultaneously across CE markets, enabling faster clinical decisions and improved patient outcomes.

Roche's Ionify® steroid assays receive FDA's moderate complexity designation, expanding access to mass spectrometry-based hormone testing across routine clinical laboratories.

Roche and NVIDIA expand AI infrastructure with 2,176 on-premises GPUs across U.S. and Europe, totaling 3,500 Blackwell units to accelerate drug discovery and diagnostics.

Eli Lilly dominates weight-loss pharmaceuticals with 45% 2025 revenue growth, maintaining market lead despite competitor advances due to years-long regulatory timelines.

Pegasys market projected for growth via rising hepatitis B prevalence and indication expansion, though direct-acting antivirals and tariff pressures pose challenges. Asia-Pacific represents fastest-growing region.

Global molecular diagnostics market projected to reach $33.51B by 2031 at 10.43% CAGR, driven by precision medicine adoption and genomic testing advances.

Roche's giredestrant failed to meet primary endpoint in Phase 3 breast cancer trial, causing 5% stock decline. Company plans adjuvant trial readout in 2027.

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.

Roche's petrelintide demonstrates 10.7% weight reduction in Phase II, positioning the amylin analog as a potential alternative to dominant GLP-1 drugs with favorable tolerability. Phase III trials planned.

Zealand Pharma reports positive Phase 2 data for petrelintide, achieving 10.7% weight loss versus 1.7% placebo with favorable safety profile.

Global respiratory testing market projected to reach $9.32B by 2032, growing 6.50% annually from $5.99B in 2025, driven by molecular diagnostics and telemedicine innovations.

Survey of 4,326 diabetics across 22 countries shows 80% demand predictive glucose forecasting tools, revealing unmet market need beyond current continuous glucose monitoring.

GLP-1 receptor agonist market projected to surge from $51.9B in 2024 to $137.4B by 2030, driven by obesity prevalence and expanded therapeutic applications.

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.

Precision medicine market expected to double to $237.28B by 2031, driven by AI advances and biomarker development at 13.58% annual growth.

Global ophthalmic drug market projected to reach $41.88B by 2026, growing 7.9% annually driven by biologic therapies, advanced delivery systems, and AI-enabled diagnostics.

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.

FDA approves first all-oral combination therapy for untreated chronic lymphocytic leukemia. The fixed-duration treatment showed 35% reduced progression risk versus chemotherapy.

Alzheimer's therapeutics market projected to exceed $6B by 2026 driven by rising disease prevalence and increased pharma investment in disease-modifying treatments.